^
    3d
    Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Suzhou Maximum Bio-tech Co., Ltd.
    New P1 trial • Metastases
    |
    MT027
    4d
    Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Suzhou Maximum Bio-tech Co., Ltd.
    New P1 trial
    |
    MT027
    over1year
    An exploratory clinical trial on intra-lumbar injection of B7H3-specific allogeneic universal CAR-T cells in patients with recurrent high-grade gliomas. (ASCO 2023)
    In patients with rHGGs, B7H3 UCAR-T cells was not associated with any toxic effects of grade 3 or higher. B7H3 UCAR-T cells resulted in a significantly longer overall survival and a higher objective response rate than history data. B7H3 UCAR-T cells persist well in patients.
    Clinical • CAR T-Cell Therapy • IO biomarker
    |
    IL6 (Interleukin 6) • CD276 (CD276 Molecule)
    |
    MT027
    almost2years
    Safety and Efficacy of Targeted IL-13 Rα2 or B7-H3 UCAR-T for Advanced Glioma (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, Second Affiliated Hospital of Soochow University
    New trial • CAR T-Cell Therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
    |
    MT-026 • MT027